VolitionRX (NYSEAMERICAN:VNRX) announced its quarterly earnings results on Monday. The medical research company reported ($0.11) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.12) by $0.01, Morningstar.com reports.
NYSEAMERICAN:VNRX traded up $0.08 during midday trading on Tuesday, hitting $3.99. 23,820 shares of the company were exchanged, compared to its average volume of 100,148. VolitionRX has a fifty-two week low of $1.67 and a fifty-two week high of $4.65.
In other VolitionRX news, Director Martin Charles Faulkes acquired 70,731 shares of the company’s stock in a transaction on Monday, June 10th. The shares were bought at an average cost of $3.02 per share, for a total transaction of $213,607.62. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.
VolitionRX Limited, a life sciences company, engages in the development of blood tests to help diagnose a range of cancers and other diseases worldwide. The company develops blood-based Nu.Q immunoassays to detect specific biomarkers. VolitionRX Limited is based in Singapore.
Featured Story: Do Tariffs Work?
Receive News & Ratings for VolitionRX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VolitionRX and related companies with MarketBeat.com's FREE daily email newsletter.